Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS). Global real-world patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback